Literature DB >> 16159975

Tissue resident C reactive protein in degenerative aortic valves: correlation with serum C reactive protein concentrations and modification by statins.

D Skowasch1, S Schrempf, C J Preusse, J A Likungu, A Welz, B Lüderitz, G Bauriedel.   

Abstract

OBJECTIVE: To assess aortic valve probes for valvar C reactive protein (CRP) presence, the relation between valvar and serum CRP, and a possible modification of CRP by statin medication.
SETTING: Tertiary referral centre. PATIENTS AND
DESIGN: End stage, degenerative valve tissue was taken from 81 patients, 57 with non-rheumatic aortic valve stenosis (AS) and 24 with degenerative aortic valve bioprosthesis (BP). Five non-stenosed valves served as controls. Tissue from four non-implanted bioprostheses was also examined. The presence and location of CRP was analysed by use of immunostaining and morphometry. Serum CRP concentrations were measured preoperatively.
RESULTS: The majority of AS and BP valves exhibited CRP labelled cells, predominantly localised to the valvar fibrosa. The expression of CRP was much higher in BP than in AS (by a factor of 3.7, p = 0.03). Notably, non-stenosed aortic valves and non-implanted bioprostheses did not have CRP signalling. Serum CRP was also increased with BP (by a factor of 2.5, p = 0.02) and was significantly correlated with valvar CRP expression (r = 0.54, p < 0.001). The main finding in patients with (n = 26) and without statin treatment (n = 55) was that both valvar CRP expression (p = 0.02) and serum CRP concentrations (p = 0.04) were lower in the statin treated group.
CONCLUSIONS: CRP was found in a large series of degenerative aortic valves, more often in bioprostheses than in native cusps. Serum CRP concentrations may reflect inflammatory processes within the aortic valve. The association of statin treatment with decreases in both valvar and serum CRP concentrations may explain known pleiotropic effects of statins in patients with aortic stenosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16159975      PMCID: PMC1860890          DOI: 10.1136/hrt.2005.069815

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  31 in total

1.  Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons.

Authors:  W S Aronow; C Ahn; I Kronzon; M E Goldman
Journal:  Am J Cardiol       Date:  2001-09-15       Impact factor: 2.778

2.  Progression of human aortic valve stenosis is associated with tenascin-C expression.

Authors:  Jari Satta; Jukka Melkko; Raimo Pöllänen; Juha Tuukkanen; Paavo Pääkkö; Pasi Ohtonen; Ari Mennander; Ylermi Soini
Journal:  J Am Coll Cardiol       Date:  2002-01-02       Impact factor: 24.094

3.  Generation of C-reactive protein and complement components in atherosclerotic plaques.

Authors:  K Yasojima; C Schwab; E G McGeer; P L McGeer
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

4.  Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.

Authors:  G M Novaro; I Y Tiong; G L Pearce; M S Lauer; D L Sprecher; B P Griffin
Journal:  Circulation       Date:  2001-10-30       Impact factor: 29.690

5.  Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies.

Authors:  Allen P Burke; Russell P Tracy; Frank Kolodgie; Gray T Malcom; Arthur Zieske; Robert Kutys; Joseph Pestaner; John Smialek; Renu Virmani
Journal:  Circulation       Date:  2002-04-30       Impact factor: 29.690

6.  Bone formation and inflammation in cardiac valves.

Authors:  E R Mohler; F Gannon; C Reynolds; R Zimmerman; M G Keane; F S Kaplan
Journal:  Circulation       Date:  2001-03-20       Impact factor: 29.690

7.  Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs.

Authors:  V Pasceri; J S Cheng; J T Willerson; E T Yeh; J Chang
Journal:  Circulation       Date:  2001-05-29       Impact factor: 29.690

8.  C-reactive protein is increased in patients with degenerative aortic valvular stenosis.

Authors:  A Galante; A Pietroiusti; M Vellini; P Piccolo; G Possati; M De Bonis; R L Grillo; C Fontana; C Favalli
Journal:  J Am Coll Cardiol       Date:  2001-10       Impact factor: 24.094

9.  Persistence of Chlamydia pneumoniae in degenerative aortic valve stenosis indicated by heat shock protein 60 homologues.

Authors:  Dirk Skowasch; Kristina Yeghiazaryan; Stephanie Schrempf; Olga Golubnitschaja; Ulrich Welsch; Claus J Preusse; James A Likungu; Armin Welz; Berndt Lüderitz; Gerhard Bauriedel
Journal:  J Heart Valve Dis       Date:  2003-01

10.  Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community.

Authors:  Michael F Bellamy; Patricia A Pellikka; Kyle W Klarich; A Jamil Tajik; Maurice Enriquez-Sarano
Journal:  J Am Coll Cardiol       Date:  2002-11-20       Impact factor: 24.094

View more
  10 in total

1.  C-reactive protein and subclinical cardiovascular disease among African-Americans: (the Jackson Heart Study).

Authors:  Jung Hye Sung; Jae Eun Lee; Tandaw E Samdarshi; Harsha S Nagarajarao; Jason K Taylor; Khushboo K Agrawal; Herman A Taylor; Ervin R Fox
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2014-05       Impact factor: 2.160

Review 2.  Can statins improve outcomes after isolated cardiac valve surgery? A systematic literature review.

Authors:  Jacob Chacko; Leanne Harling; Hutan Ashrafian; Thanos Athanasiou
Journal:  Clin Cardiol       Date:  2013-05-13       Impact factor: 2.882

3.  Antibodies against C-reactive protein cross-react with 60-kilodalton heat shock proteins.

Authors:  Katalin Udvarnoki; László Cervenak; Katalin Uray; Ferenc Hudecz; Imre Kacskovics; Ralf Spallek; Mahavir Singh; George Füst; Zoltán Prohászka
Journal:  Clin Vaccine Immunol       Date:  2007-02-14

Review 4.  Role of oxidative stress in calcific aortic valve disease and its therapeutic implications.

Authors:  Harry Z E Greenberg; Guoan Zhao; Ajay M Shah; Min Zhang
Journal:  Cardiovasc Res       Date:  2022-05-06       Impact factor: 13.081

Review 5.  Is there a role of statins in the prevention of aortic biological prostheses degeneration.

Authors:  Francesco Antonini-Canterin; Alfredo Zuppiroli; Ferdinando Baldessin; Bogdan A Popescu; Gian Luigi Nicolosi
Journal:  Cardiovasc Ultrasound       Date:  2006-06-29       Impact factor: 2.062

Review 6.  C-reactive protein in aortic valve disease.

Authors:  Pedro L Sanchez; Anna Maria Mazzone
Journal:  Cardiovasc Ultrasound       Date:  2006-10-16       Impact factor: 2.062

Review 7.  C-reactive protein in degenerative aortic valve stenosis.

Authors:  Pedro L Sanchez; AnnaMaria Mazzone
Journal:  Cardiovasc Ultrasound       Date:  2006-06-14       Impact factor: 2.062

8.  Degenerative valve disease and bioprostheses: risk assessment, predictive diagnosis, personalised treatments.

Authors:  Kristina Yeghiazaryan; Dirk Skowasch; Gerhard Bauriedel; Hans H Schild; Olga Golubnitschaja
Journal:  EPMA J       Date:  2011-04-03       Impact factor: 6.543

9.  The Prognostic Value of C-reactive Protein to Albumin Ratio in Patients with Isolated Degenerative Aortic Valve Stenosis Undergoing Surgical Aortic Valve Replacement.

Authors:  Serkan Kahraman; Arda Can Dogan; Gokhan Demirci; Ali Riza Demir; Emre Yilmaz; Hicaz Zencirkiran Agus; Ali Kemal Kalkan; Fatih Uzun; Mehmet Erturk
Journal:  Braz J Cardiovasc Surg       Date:  2020-06-01

10.  Degeneration of Bioprosthetic Heart Valves: Update 2020.

Authors:  Alexander E Kostyunin; Arseniy E Yuzhalin; Maria A Rezvova; Evgeniy A Ovcharenko; Tatiana V Glushkova; Anton G Kutikhin
Journal:  J Am Heart Assoc       Date:  2020-09-21       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.